1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Okines A, Verheij M, Allum W, Cunningham D
and Cervantes A; ESMO Guidelines Working Group. Gastric cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 21(Suppl 5): v50–v54. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zhang D and Fan D: New insights into the
mechanisms of gastric cancer multidrug resistance and future
perspectives. Future Oncol. 6:527–537. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Taby R and Issa JP: Cancer epigenetics. CA
Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ushijima T: Epigenetic field for
cancerization. J Biochem Mol Biol. 40:142–150. 2007. View Article : Google Scholar
|
6
|
Shen L, Kondo Y, Ahmed S, et al: Drug
sensitivity prediction by CpG island methylation profile in the
NCI-60 cancer cell line panel. Cancer Res. 67:11335–11343. 2007.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Yamashita S, Takahashi S, McDonell N, et
al: Methylation silencing of transforming growth factor-β receptor
type II in rat prostate cancers. Cancer Res. 68:2112–2121.
2008.
|
8
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bibikova M, Barnes B, Tsan C, et al: High
density DNA methylation array with single CpG site resolution.
Genomics. 98:288–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Colella S, Shen L, Baggerly KA, Issa JP
and Krahe R: Sensitive and quantitative universal Pyrosequencing
methylation analysis of CpG sites. Biotechniques. 35:146–150.
2003.PubMed/NCBI
|
11
|
An B, Kondo Y, Okamoto Y, et al:
Characteristic methylation profile in CpG island methylator
phenotype-negative distal colorectal cancers. Int J Cancer.
127:2095–2105. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Shen L, Guo Y, Chen X, Ahmed S and Issa
JP: Optimizing annealing temperature overcomes bias in bisulfite
PCR methylation analysis. Biotechniques. 42:48–58. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chou RH, Lin SC, Wen HC, Wu CW and Chang
WS: Epigenetic activation of human kallikrein 13 enhances
malignancy of lung adenocarcinoma by promoting N-cadherin
expression and laminin degradation. Biochem Biophys Res Commun.
409:442–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Florou D, Mavridis K and Scorilas A: The
kallikrein-related peptidase 13 (KLK13) gene is
substantially up-regulated after exposure of gastric cancer cells
to antineoplastic agents. Tumour Biol. 33:2069–2078. 2012.
|
15
|
Gu X, Shin BH, Akbarali Y, et al: Tel-2 is
a novel transcriptional repressor related to the Ets factor
Tel/ETV-6. J Biol Chem. 276:9421–9436. 2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hanker LC, Karn T, Holtrich U, et al:
Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer.
Anticancer Res. 33:371–377. 2013.PubMed/NCBI
|
17
|
Tsai WC, Jin JS, Chang WK, et al:
Association of cortactin and fascin-1 expression in gastric
adenocarcinoma: correlation with clinicopathological parameters. J
Histochem Cytochem. 55:955–962. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Reilly PT and Mak TW: Molecular pathways:
tumor cells co-opt the brain-specific metabolism gene CPT1C
to promote survival. Clin Cancer Res. 18:5850–5855. 2012.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Liu J, Fan H, Ma Y, et al: Notch1 is a
5-fluorouracil resistant and poor survival marker in human
esophagus squamous cell carcinomas. PLoS One. 8:e561412013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Ma XB, Jia XS, Liu YL, et al: Expression
and role of Notch signalling in the regeneration of rat tracheal
epithelium. Cell Prolif. 42:15–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Man CH, Wei-Man Lun S, Wai-Ying Hui J, et
al: Inhibition of NOTCH3 signalling significantly enhances
sensitivity to cisplatin in EBV-associated nasopharyngeal
carcinoma. J Pathol. 226:471–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Rahman MT, Nakayama K, Rahman M, et al:
Notch3 overexpression as potential therapeutic target in advanced
stage chemoresistant ovarian cancer. Am J Clin Pathol. 138:535–544.
2012. View Article : Google Scholar : PubMed/NCBI
|